Fluocinolone acetonide micro-insert intravitreous implant - pSivida

Drug Profile

Fluocinolone acetonide micro-insert intravitreous implant - pSivida

Alternative Names: DF-277; Durasert™ three-year uveitis insert; FAI insert; Fluocinolone; Fluocinolone acetonide intravitreal insert; Iluvien; Injectable micro-insert - pSivida; Medidur; Medidur-FA; NSC-92339; Ophthalmic implant - Alimera Sciences/pSivida

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator pSivida Inc
  • Developer Alimera Sciences; Johns Hopkins University; pSivida Inc
  • Class Anti-inflammatories; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic macular oedema
  • Phase III Uveitis
  • No development reported Dry age-related macular degeneration; Retinal vascular occlusion; Wet age-related macular degeneration

Most Recent Events

  • 02 Nov 2016 MEAgate initiates Named Patient Access Programme for Fluocinolone acetonide micro-insert intravitreous implant in Saudi Arabia, Egypt, United Arab Emirates, Lebanon and other middle eastern countries before November 2016
  • 04 Oct 2016 pSivida announces intention to submit MAA to the European Medicines Agency in the first quarter of 2017 for Uveitis
  • 04 Oct 2016 pSivida announces intention to submit NDA to the US FDA for the treatment of Uveitis in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top